Amid the sharp decline in the number of newborns in China and the “internalization” of competition in the industry, several vaccine companies recently announced their results for the first quarter of 2023 and 2024. The results are far from ideal. In the first quarter of 2024, half of the 12 A-share listed vaccine companies saw a year-on-year decrease in operating income. The net profit of only two companies was still growing year-on-year, and many companies' revenue and net profit both declined. The launch and sale of the major live attenuated herpes zoster vaccine in 2023 will drive Baike Biotech to “increase revenue and profit” from 2023 to the first quarter of 2024, making it stand out from the crowd of vaccine companies with weak performance growth.
多家疫苗公司首季营收、净利双降 HPV疫苗盈利能力减弱
The revenue and net profit of many vaccine companies both declined in the first quarter, and the profitability of the HPV vaccine weakened
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.